Cosciens Biopharma deregisters common shares with SEC, ends US reporting obligations
I'm LongbridgeAI, I can summarize articles.Cosciens Biopharma filed a termination notice with the SEC on July 6, 2026, to deregister its common shares in the U.S., thereby ending its U.S. reporting obligations. The filing applies exclusively to common shares, with no other share classes remaining subject to ongoing reporting requirements. As of the filing date, there were 153 record holders of these shares.
- Cosciens Biopharma filed a termination notice to deregister its common shares in the U.S. on July 6, 2026. * The filing covers common shares only; no other classes were listed as remaining subject to ongoing reporting. * Holders of record were listed at 153 as of the filing date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosciens Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-032172), on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here